Abstract:Background and Objective: Previous studies have identified associations between metabolites and Parkinson's disease (PD), but the causal relationships remain unclear. This study aims to identify causal relationships between specific cerebrospinal fluid (CSF) and plasma metabolites and the PD risk using Mendelian Randomization (MR). Methods: We utilized data on 338 CSF metabolites from the Wisconsin Alzheimer's Disease Research Center and the Wisconsin Registry for Alzheimer's Prevention, and 1,400 plasma metabolites from the Canadian Longitudinal Study on Aging. PD outcome data were obtained from a GWAS meta-analysis by the International Parkinson's Disease Genomics Consortium. MR analysis was conducted using the TwoSampleMR package in R. Results: MR analysis identified 49 plasma metabolites with suggestive causal relationships with PD risk, including 21 positively associated metabolites, 23 negatively associated metabolites, and 5 unknown compounds. In the CSF, six metabolites showed suggestive causal relationships with PD, including positively associated dimethylglycine, gluconate, oxalate (ethanedioate), and the unknown metabolite X-12015, while (1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) and the unknown metabolite X-23587 were negatively associated. Among the plasma metabolites, those with a positive association with PD risk include hydroxy-3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (hydroxy-CMPF), carnitine C14, 1-linoleoyl-GPG (18:2), glucose to maltose ratio, and cis-3,4-methyleneheptanoate. Conversely, metabolites with a negative association with PD risk include tryptophan, succinate to acetoacetate ratio, N,N,N-trimethyl-alanylproline betaine (TMAP), glucuronide of piperine metabolite C17H21NO3, and linoleoylcholine. Conclusion: Our study underscores the correlation between CSF and plasma metabolites and PD risk, highlighting specific metabolites as potential biomarkers for diagnosis and therapeutic targets.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to identify the causal relationships between specific cerebrospinal fluid (CSF) and plasma metabolites and the risk of Parkinson's disease (PD) through the Mendelian Randomization (MR) method. Specifically, the study aims to: 1. **Determine causal relationships**: Use genetic variants as instrumental variables to evaluate the causal relationships between specific metabolites in CSF and plasma and the risk of PD. 2. **Discover potential biomarkers**: Identify metabolites that may serve as targets for PD diagnosis and treatment. 3. **Verify metabolic pathways**: Through metabolic pathway analysis, understand the specific metabolic pathways involved in the pathogenesis of PD by these metabolites. ### Background and Objectives Parkinson's disease is a progressive neurodegenerative disease, mainly characterized by the loss of dopaminergic neurons in the substantia nigra, resulting in symptoms such as tremors, bradykinesia, and rigidity. Despite extensive research, the exact cause of PD remains unclear, involving complex interactions of genetic, environmental, and lifestyle factors. Metabolomics, as a method for comprehensively studying small - molecule metabolites in biological systems, has revealed significant metabolic disorders in CSF and plasma in PD patients. However, it is not clear whether these associations are causal. ### Methods - **Data sources**: The study used plasma metabolite data from 8,299 participants (aged 45 - 85 years) in the Canadian Longitudinal Study on Aging, and data on 338 CSF metabolites from the Wisconsin Alzheimer's Disease Research Center and the Wisconsin Alzheimer's Disease Prevention Registry. - **Outcome data**: PD outcome data were from the GWAS meta - analysis of the International Parkinson's Disease Genomics Consortium. - **Instrument selection**: Appropriate single - nucleotide polymorphisms (SNPs) were selected as instrumental variables through a strict screening process to ensure their independence and effectiveness. - **Statistical analysis**: MR analysis was performed using the TwoSampleMR package in R language, with the inverse - variance - weighted (IVW) method as the main analysis method, supplemented by four other MR methods (MR - Egger, weighted median, simple mode, and weighted mode). ### Results - **CSF metabolites**: The study found that six CSF metabolites had suggestive causal relationships with PD risk, of which four were positively correlated and two were negatively correlated. - **Plasma metabolites**: The study found that 49 plasma metabolites had suggestive causal relationships with PD risk, of which 21 were positively correlated, 23 were negatively correlated, and five were unknown compounds. - **Metabolic pathway analysis**: Metabolic pathway analysis performed by MetaboAnalyst 6.0 revealed 15 significant metabolic pathways, including the urea cycle and alanine metabolism. ### Conclusions This study provides strong evidence for the metabolic basis of Parkinson's disease through the MR method and identifies the causal relationships between specific CSF and plasma metabolites and PD risk. These metabolites may serve as potential biomarkers for PD diagnosis and treatment. Further research will help to validate these findings and explore their clinical applications, thereby improving the understanding of the pathogenesis of PD and the prognosis of patients.

Cerebrospinal Fluid and Plasma Metabolites with Parkinson's Disease: A Mendelian Randomization Study

Causal association between plasma metabolites and neurodegenerative diseases

Metabolite Associations with Childhood and Juvenile Absence Epilepsy: A Bidirectional Mendelian Randomization Study

Plasma lipidome, circulating inflammatory proteins, and Parkinson's disease: a Mendelian randomization study

Exploring the causal link between serum amino acids and Parkinson's disease: a Mendelian randomization approach

Investigating Casual Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases: A Mendelian Randomization Study

Mendelian Randomization Analysis of the Brain, Cerebrospinal Fl Uid, and Plasma Proteome Identi Fi Es Potential Drug Targets for Attention De Fi Cit Hyperactivity Disorder

Elucidating the Causal Links Between Plasma and Cerebrospinal Fluid Metabolites and Pituitary Tumors: a Mendelian Randomization Analysis

Causal role of immune cells on risk of Parkinson's disease: a Mendelian randomization study

Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome-Wide Association Study

Investigating the causality of metabolites involved in one-carbon metabolism with the risk and age at onset of Parkinson's disease: A two-sample mendelian randomization study

Investigating the Genetic Association of 40 Biochemical Indicators with Parkinson's Disease

Systematic genome-wide Mendelian randomization reveals the causal links between miRNAs and Parkinson's disease

The causal relationship between CSF metabolites and GBM: a two-sample mendelian randomization analysis

Effect of plasma vitamin C levels on Parkinson’s disease and age at onset: a Mendelian randomization study

Association of genetically predicted 486 blood metabolites on the risk of Alzheimer's disease: a Mendelian randomization study

Causal Association between Circulating Metabolites and Dementia: A Mendelian Randomization Study

Causal influence of plasma metabolites on age-related macular degeneration: A Mendelian randomization study

Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry

Assessing the causal effect of genetically predicted metabolites and metabolic pathways on stroke

Identifying potential repurposable medications for Parkinson's disease through Mendelian randomization analysis